AstraZeneca-AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs

AstraZeneca’s (AZN) first-quarter 2025 core earnings of $1.24 per American depositary share (ADS) beat the Zacks Consensus Estimate of$ 1.10. Core earnings of $2.49 per share rose 21% year over year on a reported basis as well as at constant exchange rates (CER).Total revenues of$ 13.59 billion rose 7% on a reported basis and 10% at CER, driven by higher product sales and alliance revenues from partnered medicines. However, the metric missed the Zacks Consensus Estimate of $13.68 billion. (Find the latest E ...